vs
Side-by-side financial comparison of DiamondRock Hospitality Co (DRH) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
DiamondRock Hospitality Co is the larger business by last-quarter revenue ($258.2M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -8.6%).
DiamondRock Hospitality Co is a US-based real estate investment trust owning and operating a portfolio of premium upscale hotels and resorts. Its properties are mainly located in major urban tourist and business hubs nationwide, catering to both leisure and corporate clientele seeking high-quality accommodation services.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
DRH vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $258.2M | $168.4M |
| Net Profit | $14.5M | — |
| Gross Margin | — | — |
| Operating Margin | 11.1% | 50.6% |
| Net Margin | 5.6% | — |
| Revenue YoY | 1.3% | 143.7% |
| Net Profit YoY | 22.0% | — |
| EPS (diluted) | $0.07 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $258.2M | — | ||
| Q4 25 | $274.5M | $168.4M | ||
| Q3 25 | $285.4M | $87.3M | ||
| Q2 25 | $305.7M | $82.4M | ||
| Q1 25 | $254.9M | $65.0M | ||
| Q4 24 | $279.1M | $69.1M | ||
| Q3 24 | $285.1M | $51.6M | ||
| Q2 24 | $309.3M | $73.8M |
| Q1 26 | $14.5M | — | ||
| Q4 25 | $26.2M | — | ||
| Q3 25 | $22.5M | $-31.3M | ||
| Q2 25 | $40.8M | $-12.7M | ||
| Q1 25 | $11.9M | $-40.5M | ||
| Q4 24 | $-11.2M | — | ||
| Q3 24 | $26.4M | $-29.5M | ||
| Q2 24 | $24.5M | $-61.9M |
| Q1 26 | 11.1% | — | ||
| Q4 25 | 8.9% | 50.6% | ||
| Q3 25 | 8.1% | -11.4% | ||
| Q2 25 | 13.7% | 8.6% | ||
| Q1 25 | 4.3% | -34.0% | ||
| Q4 24 | -3.7% | -6.4% | ||
| Q3 24 | 9.5% | -31.0% | ||
| Q2 24 | 8.4% | 3.5% |
| Q1 26 | 5.6% | — | ||
| Q4 25 | 9.5% | — | ||
| Q3 25 | 7.9% | -35.9% | ||
| Q2 25 | 13.4% | -15.4% | ||
| Q1 25 | 4.7% | -62.2% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | 9.3% | -57.2% | ||
| Q2 24 | 7.9% | -83.9% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.12 | $0.32 | ||
| Q3 25 | $0.10 | $-0.16 | ||
| Q2 25 | $0.18 | $-0.06 | ||
| Q1 25 | $0.04 | $-0.21 | ||
| Q4 24 | $-0.06 | $-0.14 | ||
| Q3 24 | $0.11 | $-0.15 | ||
| Q2 24 | $0.10 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.3M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $-302.0M |
| Total Assets | $3.0B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $39.3M | — | ||
| Q4 25 | $68.1M | $167.9M | ||
| Q3 25 | $145.3M | $92.4M | ||
| Q2 25 | $52.4M | $86.1M | ||
| Q1 25 | $100.6M | $114.6M | ||
| Q4 24 | $81.4M | $144.8M | ||
| Q3 24 | $75.3M | $144.7M | ||
| Q2 24 | $125.2M | $189.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $-302.0M | ||
| Q3 25 | $1.6B | $-451.4M | ||
| Q2 25 | $1.6B | $-433.5M | ||
| Q1 25 | $1.6B | $-426.2M | ||
| Q4 24 | $1.6B | $-388.7M | ||
| Q3 24 | $1.6B | $-370.2M | ||
| Q2 24 | $1.6B | $-344.2M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $465.9M | ||
| Q3 25 | $3.1B | $364.0M | ||
| Q2 25 | $3.1B | $347.1M | ||
| Q1 25 | $3.1B | $324.0M | ||
| Q4 24 | $3.2B | $343.8M | ||
| Q3 24 | $3.2B | $314.1M | ||
| Q2 24 | $3.2B | $352.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.71× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $67.9M | $45.2M | ||
| Q3 25 | $74.6M | $-4.3M | ||
| Q2 25 | $73.6M | $-31.4M | ||
| Q1 25 | $27.6M | $-22.6M | ||
| Q4 24 | $75.8M | $-35.0M | ||
| Q3 24 | $61.7M | $-35.3M | ||
| Q2 24 | $55.7M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | $47.3M | — | ||
| Q3 25 | $54.9M | — | ||
| Q2 25 | $57.9M | — | ||
| Q1 25 | $2.0M | — | ||
| Q4 24 | $52.6M | — | ||
| Q3 24 | $39.0M | $-35.5M | ||
| Q2 24 | $38.8M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 17.2% | — | ||
| Q3 25 | 19.2% | — | ||
| Q2 25 | 18.9% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 18.9% | — | ||
| Q3 24 | 13.7% | -68.7% | ||
| Q2 24 | 12.5% | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | 7.5% | 0.0% | ||
| Q3 25 | 6.9% | 0.0% | ||
| Q2 25 | 5.1% | 0.0% | ||
| Q1 25 | 10.0% | 0.0% | ||
| Q4 24 | 8.3% | 0.0% | ||
| Q3 24 | 7.9% | 0.3% | ||
| Q2 24 | 5.5% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.59× | — | ||
| Q3 25 | 3.31× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 2.33× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.33× | — | ||
| Q2 24 | 2.27× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DRH
| Rooms | $164.1M | 64% |
| Food and beverage | $67.2M | 26% |
| Other | $26.9M | 10% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
